MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why SRZN Stock dropped -2.93% Today — RQD Quant Desk Flash
$29.46 -2.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $29.25
Surrozen Inc. (SRZN) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $524.4M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $29.25 (-0.72%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-14% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRZN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY SRZN SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (30% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (22% of score)
FRED Regime × Technicals: 68% of 52W Range • RSI-14 at 58 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$29.69-21.1% Next Q
35
Q2 (-2Q)Grade E$23.44+8.7% Next Q
32
Q3 (-1Q)Grade E$25.48+15.6% Next Q
30
CurrentGrade E$29.46-10.3% Hist 90D α
27
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SRZN Turnaround Squeeze
While SRZN currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.31) and Max Pain ($30.93) forces dealer call-delta covering toward $39.72.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRZN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SRZN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SRZN Stock dropped -2.93% Today — RQD Quant Desk Flash
Surrozen Inc. (SRZN) dropped -2.93% to $29.46, trading at 68% of its 52-week range ($11.39 – $37.83). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 68% of its 52-week range ($11.39 – $37.83) with RSI-14 at 58 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $29.46 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live SRZN Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRZN)
- ✓Walkthrough of SRZN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SRZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.80%📐 HORIZONTAL RANGE
2026-10-30O $29.32H $29.51L $27.72C $29.46VOL 231.9K
RES: $42.49SUP: $14.77SMA50: $24.31SMA200: $25.10
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SRZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SRZN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SRZN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SRZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRZN)
Health Care Rank #975 of 1016
⚔️ VALN vs SRZN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SRZN vs. VALN, ETRA, ENTX, RGNX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Surrozen Inc. (SRZN) ranks #975 by composite RQD confidence (27/100, grade E) and #438 by equity capitalization ($524.4M). Within this direct 5-issuer industry benchmark cohort, SRZN leads on earnings valuation at N/A trailing P/E, while ENTX leads on capital efficiency and profitability with -33.6% ROIC and 0.0% gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with SRZN at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SRZN
ACTIVE
Surrozen Inc. | E | 27/100 | — | — | -35.0% | -2.93% | $524.4M | Benchmark Subject |
| VALN Valneva SE | D+ | 58/100 | — | — | — | -0.52% | $541.8M | /valn-vs-srzn → |
| ETRA Electra Therapeutics Inc. | D | 48/100 | — | — | — | -3.79% | $542.3M | /etra-vs-srzn → |
| ENTX Entera Bio Ltd. | D- | 40/100 | — | 0.0% | -33.6% | +0.65% | $542.6M | /entx-vs-srzn → |
| RGNX REGENXBIO Inc. | D- | 39/100 | — | — | -35.0% | +2.35% | $489.2M | /rgnx-vs-srzn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001824893In its most recent audited fiscal period (FY2025, filed 2025-12-31), Surrozen Inc. (SRZN) reported GAAP revenue of $3.5M (-67.4% vs. FY2024 revenue of $10.7M ) , GAAP net income of -$242.0M, operating cash flow of -$30.2M, and free cash flow of -$30.4M (-72.0% YoY). On the balance sheet, SRZN closed FY2025 with $98.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.5M | -$242.0M | -$30.2M | -$30.4M | $98.7M | — |
| FY2024 (FY) | 2024-12-31 | $10.7M | -$63.6M | -$17.6M | -$17.7M | $48.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$43.0M | -$40.4M | -$40.4M | — | — |
3. SRZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SRZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Surrozen Inc. (NASDAQ: SRZN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $29.46 (-2.93% 1D, market cap $524.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SRZN ranks #975 in composite RQD confidence.
How does SRZN compare to VALN and ETRA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SRZN carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VALN (Valneva SE) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $541.8M) and ETRA (Electra Therapeutics Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $542.3M). Among the 5-stock peer group, SRZN leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SRZN?
Per SRZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001824893), Surrozen Inc. generated $3.5M in revenue (-67.4% YoY), -$242.0M in net income, and -$30.4M in free cash flow against $98.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SRZN trading relative to its 50-day, 200-day, and 52-week technical levels?
SRZN last traded at $29.46 (-2.93% on volume of 254,742 shares), positioning the stock +21.18% above its 50-day simple moving average ($24.31) and +17.37% above its 200-day simple moving average ($25.10). Across its 52-week range of $11.39 to $37.83, SRZN sits at the 68.3% percentile with a 14-day RSI of 58.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($25.78 to $33.14).
SRZN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SRZN stock moving today?
Why SRZN Stock dropped -2.93% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.